# EDGAR Filing Document

**Accession Number:** 0000856984
**File Stem:** 0001641172-25-013369
**Filing Date:** 2025-6
**Character Count:** 13536
**Document Hash:** 65de5102fa0eadc60dc4282646450b82
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-013369.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001641172-25-013369

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250603

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QHSLab, Inc.
- **CENTRAL INDEX KEY:** 0000856984
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112655906
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19041
- **FILM NUMBER:** 251017230

**BUSINESS ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407
- **BUSINESS PHONE:** (929) 379-6503

**MAIL ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITIES CORP.
- **DATE OF NAME CHANGE:** 20151119

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITY CORP.
- **DATE OF NAME CHANGE:** 20151116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERICAN BIOGENETIC SCIENCES INC
- **DATE OF NAME CHANGE:** 19940426

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (date of earliest event reported): June 3, 2025

**<u>QHSLab, Inc.</u>**

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

<u>Nevada</u> <u>30-1104301</u> <br> (State of Incorporation) (I.R.S. Employer Identification No.)

<u>901 Northpoint Parkway Suite 302 West Palm Beach FL 33407</u> <u>33407</u> <br> (Address of Principal Executive Offices) (ZIP Code)

Registrant's telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

**Securities registered pursuant to Section 12(g) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $0.0001 par value** | **USAQ** | **N/A** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On June 3, 2025, QHSLab, Inc. (the "Company") issued a press release titled *"QHSLab, Inc. Publishes Peer-Reviewed Studies Validating Digital Tools for Enhancing Patient Outcomes and Healthcare Efficiency."* A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (<u>https://twitter.com/qhslabinc</u>), LinkedIn account (<u>https://www.linkedin.com/company/65407282/</u>), Facebook account (<u>https://www.facebook.com/QHSLabs)</u> and Instagram account (<u>https://www.instagram.com/qhslabs/)</u> as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

**Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release dated June 3, 2025 – QHSLab, Inc. Publishes Peer-Reviewed Studies Validating Digital Tools for Enhancing Patient Outcomes and Healthcare Efficiency](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Date: June 3, 2025 | Date: June 3, 2025 |
| QHSLab, Inc. | QHSLab, Inc. |
|  | */s/ Troy Grogan* |
| Name: | Troy Grogan |
| Title: | CEO and Chairman |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**QHSLab, Inc. Publishes Peer-Reviewed Studies Validating Digital Tools for Enhancing Patient**

**Outcomes and Healthcare Efficiency**

*Recent publications highlight the efficacy of QHSLab's digital assessments in primary care, offering benefits for providers, patients, and practice revenue.* 

**WEST PALM BEACH, FL, June 3, 2025 (GLOBE NEWSWIRE) — QHSLab Inc. (the "Company") (OTCQB: USAQ)**, a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, announces the publication of two significant peer-reviewed studies in the last week of May 2025. These studies validate the clinical effectiveness and economic benefits of QHSLab's digital assessment tools in primary care settings.

**Key Findings:**

● **Impact of help-seeking behaviors on allergic rhinitis and mental health: A longitudinal study:** 

Published in the *Journal of Psychosomatic Research*, this study shows that patients with allergic rhinitis who actively seek help seem to experience better mental health outcomes over time. Help-seeking behavior was found to be associated with a reduction of the negative impact of allergy symptoms on anxiety and depression, highlighting the value of encouraging early intervention and integrated care in primary care settings.

● **Development and Validation of the Q-Scale:** 

Featured in *Consultant360*, this study introduces the Q-Scale, a tool designed to predict healthcare overutilization by assessing patients' psychosocial, affective, and somatic factors. The Q-Scale enables primary care providers to identify high-risk patients and implement targeted interventions, optimizing resource utilization and reducing unnecessary healthcare visits.

**Leadership Commentary**

**Troy Grogan, Chief Executive Officer of QHSLab, Inc., commented:**

"These studies are a clear signal to the market that QHSLab is not only operating in high-growth areas of healthcare—mental health, preventative screening, and AI-supported care—but is doing so with scientific and economic validation. For our shareholders, this research supports our commercial claims and strengthens the foundation for reimbursement, provider adoption, and revenue growth. We're aligning scientific advancement with scalable business outcomes, and that's how we intend to deliver long-term value to our investors."

**Dr. Marcos A. Sanchez-Gonzalez, MD, PhD, VP of Medical and Scientific Affairs, added:**

"These publications reflect years of clinical design, data collection, and validation in real-world primary care environments. The findings offer practical, evidence-based tools for providers to improve patient care through early detection, cognitive profiling, and risk stratification. For patients, these tools mean more personalized care and better outcomes. The studies demonstrate that QHSLab's digital solutions are innovative and rooted in sound scientific evidence, making the digital tools ready for widespread clinical use and improving quality of care."

**Implications for Primary Care**

● **Personalized, Early Intervention:** 

By integrating cognitive and psychosocial data into routine care, providers can tailor treatment plans to individual needs and intervene before conditions escalate.

● **Optimized Resource Utilization:** 

The Q-Scale allows for proactive care planning, reducing unnecessary visits and better allocating provider time and system resources.

● **Financial Viability for Practices:** 

These tools support CPT-coded reimbursable services, allowing providers to capture new revenue streams while delivering higher-quality care.

**Business Impact**

QHSLab's continued real world research and validation efforts further support the Company's strategy of embedding clinical-grade, reimbursable digital medicine tools into primary care settings. These publications affirm the alignment between QHSLab's scientific foundation, commercial offering, and future revenue potential.

For more information about QHSLab and our healthcare solutions, please visit <u>www.qhslab.com.</u>

**About QHSLab, Inc.**

QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients' vital signs and evaluate the effects of prescribed medicines and treatments on patients' health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.'s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues.

**Forward-Looking Statements**

Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

**Investor Relations Contact:**

Brett Maas, Managing Principal, Hayden IR, LLC

<u>brett@haydenir.com</u>

646-536-7331

<u>https://twitter.com/QHSLabInc</u>